Other Information.
−Removed: Trading Plans
−Removed: On August 15, 2025 , our Chief Medical Officer , Mark Schoenberg , entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5 - 1 (c) under the Exchange Act, to sell up to 40,000 ordinary shares.
−Removed: The trading plan expires on November 18, 2026.
−Removed: Agenus License Agreement Termination
−Removed: November 2025, we provided notice to terminate the license agreement with Agenus in connection with our decision to discontinue development of UGN-
−Removed: Under the terms of the license agreement, following notice of termination, the agreement will terminate upon the later of (a) the expiration of a
−Removed: 180 -day notice period;
−Removed: or (b) completion of all wind-down activities and delivery of all Agenus Improvements (as defined in the license agreement) to Agenus.
−Removed: not expect to incur any costs in connection with the termination of the agreement.
−Removed: Lease Extension
−Removed: August 8, 2025, we entered into an amendment to our lease agreement, dated
−Removed: November 4, 2019, between us and Witman Properties, L.L.C.
−Removed: and Alexander Road at Davanne, L.L.C.
−Removed: (collectively, the “Landlord”).
−Removed: Pursuant to the amendment, we extended the expiration date of the lease from
−Removed: January 31, 2026 to
−Removed: April 30, 2031.
−Removed: Commencing with the extension term on
−Removed: February 1, 2026, our base rent will be approximately
−Removed: $0.6 million per year, or approximately
−Removed: $3.0 million in total during the extension term.
−Removed: The foregoing summary of the lease amendment is qualified in its entirety by reference to the lease amendment, a copy of which is filed as Exhibit
−Removed: 10.1 to this Quarterly Report.
The following exhibits are filed as part of this report:
1 unchanged sentence
001-38079), filed with the SEC on May 18, 2017).
−Removed: Amendment to Lease Agreement, dated August 8, 2025, by and between the Registrant and Witman Properties, L.L.C.
−Removed: and Alexander Road at Davanne, L.L.C.
+Added: Second Amended and Restated Loan Agreement, dated as of February 26, 2026, by and among UroGen Pharma, Inc., as borrower and a Credit Party, the Registrant, as Parent and a Credit Party, the other guarantors signatory thereto or otherwise party thereto from time to time, as additional Credit Parties, BioPharma Credit PLC, as Collateral Agent, BPCR Limited Partnership, as a Lender, and BioPharma Credit Investments V (Master) LP as a Lender.
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
14 unchanged sentences
UroGen Pharma Ltd.
−Removed: November 6, 2025
/s/ Elizabeth Barrett
2 unchanged sentences
(Principal Executive Officer)
−Removed: November 6, 2025
/s/ Chris Degnan
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.